EnGene provided an update after a prior May setback in its bladder cancer therapy durability data had hurt the company’s stock. The latest reported data looked better than the earlier cut, though the update suggests remaining uncertainty around the durability profile. For investors, the near-term issue remains whether the corrected or additional evidence can re-establish confidence in long-term benefit durability—an endpoint that often governs market and partnership valuation. The update also illustrates how re-iterations in oncology development narratives can materially influence trading sentiment even before controlled confirmatory readouts.